Pages that link to "Q88248387"
Jump to navigation
Jump to search
The following pages link to Bruce D. Cheson (Q88248387):
Displaying 50 items.
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines (Q24616084) (← links)
- Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia (Q24675399) (← links)
- The role of idelalisib in the treatment of relapsed and refractory chronic lymphocytic leukemia (Q26751006) (← links)
- Staging and response assessment in lymphomas: the new Lugano classification (Q26823706) (← links)
- Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia (Q28140129) (← links)
- Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development (Q28245741) (← links)
- Idelalisib and rituximab in relapsed chronic lymphocytic leukemia (Q28306347) (← links)
- Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma (Q28314924) (← links)
- Clinical toxicity associated with tiazofurin (Q28331161) (← links)
- Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma. (Q30252598) (← links)
- Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study (Q30435188) (← links)
- Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. (Q31510390) (← links)
- Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia (Q33329122) (← links)
- Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia. (Q33343988) (← links)
- Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. (Q33374864) (← links)
- Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206. (Q33375800) (← links)
- Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study (Q33378194) (← links)
- Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma (Q33378734) (← links)
- Oblimersen for the treatment of patients with chronic lymphocytic leukemia (Q33379565) (← links)
- Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma (Q33380352) (← links)
- Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia (Q33381678) (← links)
- Bortezomib, Bendamustine, and Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma: The Phase II VERTICAL Study (Q33396465) (← links)
- The Plk1 inhibitor BI 2536 in patients with refractory or relapsed non-Hodgkin lymphoma: a phase I, open-label, single dose-escalation study (Q33403311) (← links)
- A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors (Q33415880) (← links)
- Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma (Q33418257) (← links)
- Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108. (Q33423638) (← links)
- Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial (Q33433426) (← links)
- Suramin therapy in AIDS and related disorders. Report of the US Suramin Working Group (Q33454926) (← links)
- Splenectomy for Immune Thrombocytopenic Purpura (Q33486024) (← links)
- Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. (Q33498422) (← links)
- Phase II and dose-escalation with or without granulocyte colony-stimulating factor study of 9-aminocamptothecin in relapsed and refractory lymphomas (Q33503047) (← links)
- Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study (Q33572807) (← links)
- Clinical Roundtable Monograph: current treatment options for NHL patients refractory to standard therapy: recent data in single-agent and combination therapy. (Q33659247) (← links)
- Future strategies toward the cure of indolent B-cell malignancies: introduction. (Q33755668) (← links)
- New chemotherapeutics strategies for the treatment of indolent lymphoid malignancies. (Q33755688) (← links)
- Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group (Q33773306) (← links)
- Management of chronic lymphocytic leukaemia (Q33873273) (← links)
- The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance). (Q33877409) (← links)
- Role of bendamustine in the treatment of chronic lymphocytic leukemia (Q33916026) (← links)
- Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens (Q34018599) (← links)
- Emerging therapies and future directions in chronic lymphocytic leukaemia--chemotherapy (Q34063632) (← links)
- Novel therapeutic agents for the treatment of myelodysplastic syndromes. (Q34069178) (← links)
- Homoharringtonine: history, current research, and future direction (Q34105271) (← links)
- Bendamustine: mechanism of action and clinical data. (Q34169315) (← links)
- New drug development in non-Hodgkin lymphomas (Q34214872) (← links)
- Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism (Q34231085) (← links)
- Basophilic stippling of red blood cells: A nonspecific finding of multiple etiology (Q34250257) (← links)
- Novel therapies for chronic lymphocytic leukemia (Q34304235) (← links)
- National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment (Q34382878) (← links)
- Rational approaches to design of therapeutics targeting molecular markers (Q34448686) (← links)